<DOC>
	<DOCNO>NCT02323620</DOCNO>
	<brief_summary>This multicentre , randomise open-label , control , parallel-group phase III study . Its aim demonstrate triple intracoronary infusion autologous bone marrow-derived mononuclear cell addition state art treatment safe reduce all-cause mortality patient reduce left ventricular ejection fraction ( ≤45 % ) successful reperfusion acute myocardial infarction compare control group patient undergo best medical care .</brief_summary>
	<brief_title>Impact Intracoronary Injection Autologous BMMC LV Contractility Remodeling Patients With STEMI</brief_title>
	<detailed_description>The study divide 3 part : - Screening phase : Patients recruit investigational clinical center . Alternatively , patient primary PCI perform institution different investigational site also enrol . Interested patient may refer screen participate study site acute reperfusion therapy . Informed consent assessment eligibility patient respect in- exclusion criterion do investigational site . If eligibility criterion meet , echocardiography perform 3 6 day acute PCI , ejection fraction quantify central Echo Core Lab web base transmission . CT examination perform 1 month acute PCI screen patient LVEF ≤ 45 % . If LVEF improve ≥5 % CT patient may qualify Study . - Treatment phase : Bone marrow aspiration perform patient assigned treatment group ( II ) . Bone marrow collect patient MNC isolate use point-of-care system ( Harvest ) Site . Intracoronary infusion BM-MNCs perform 2 hour isolation via radial approach . Same procedure perform 3 6 month first application . - Follow-up phase : After hospital discharge , patient follow per telephone 30 day 3 , 6 , 9 month randomisation site visit CT examination 12 month randomisation . Afterwards , telephone follow perform every 3 month . Once required number clinical event observe , patient attend final study visit , minimum follow period patient 2 year . Endpoints report occur throughout follow .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>1 . Men woman ethnic origin age ≥ 18 year . 2 . Patients acute STelevation myocardial infarction define universal definition AMI . 3 . Successful acute reperfusion therapy ( residual stenosis visually &lt; 50 % TIMI flow ≥2 ) within 24 hour symptom onset thrombolysis within 12 hour symptom onset follow successful percutaneous coronary intervention ( PCI ) within 24 hour thrombolysis . 4 . Left ventricular ejection fraction ≤ 45 % significant regional wall motion abnormality assess quantitative echocardiography ( central , independent core lab analysis ) 3 6 day reperfusion therapy 5 . Open coronary artery suitable cell infusion supply target area abnormal wall motion 6 . LVEF≤45 % significant regional wall motion abnormality assess compute tomography ( CT ) 30 day reperfusion therapy LVEF improvement ≥5 % . 1 . Participation another clinical trial within 30 day prior randomisation 2 . Previously receive stem/progenitor cell therapy 3 . Pregnant nursing woman 4 . Mental condition render patient unable understand nature , scope possible consequence study follow protocol 5 . Necessity revascularise additional vessel , outside target coronary artery time BMMNC infusion ( additional revascularisations primary PCI BMMNC cell infusion allow ) 6 . Cardiogenic shock require mechanical support 7 . Platelet count &lt; 100,000/μl , hemoglobin &lt; 8.5 g/dl 8 . Impaired renal function , i.e . serum creatinine &gt; 2.5 mg/dl 9 . Persistent fever diarrhea responsive treatment within 4 week prior screen 10 . Clinically significant bleeding within 3 month prior screen 11 . Uncontrolled hypertension ( systolic &gt; 180 mmHg diastolic &gt; 120 mmHg ) 12 . Life expectancy le 2 year noncardiac cause neoplastic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Acute myocardial Infarction</keyword>
	<keyword>bone marrow</keyword>
	<keyword>stem cell</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>mortality</keyword>
</DOC>